Even though the drug is currently used for this immunosuppressive activity, the mammalian target of rapamycin (mTOR) is associated with a multitude of diseases, such as cancer, diabetes, and neurological diseases [1, 2], so many other therapeutic applications have been proposed in recent years, such as in combination cancer chemotherapy [2, 3], as an anti-aging drug [4] and as an adjuvant in antigen-specific immune tolerance generation [5–9]. This evidence concerns the gene MTOR and cancer.